Supernus Pharmaceuticals, Inc. (SUPN) Guidance & Earnings Results
On 2026-08-03 Supernus Pharmaceuticals, Inc. raised guidance: "Full year 2026 financial guidance…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SUPNSupernus Pharmaceuticals, Inc.Follow SUPN — free
—
Price chart with a free account
- Market cap
- 2.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 3 Aug 26 | Raised | Full year 2026 financial guidance raised · full year |
| 24 Feb 26 | Raised | FY2026 total revenues $840M-$870M, adjusted operating earnings $140M-$170M · full year |
| 4 Nov 25 | Raised | Increasing full year 2025 revenue guidance · full year |
| 5 Aug 25 | Raised | Full year 2025 revenue guidance increased; operating earnings guidance updated to reflect Sage acquisition. Specific numbers not provided in excerpt. · full year |
Supernus Pharmaceuticals, Inc. — questions
- What guidance did Supernus Pharmaceuticals, Inc. give?
- On 2026-08-03: "Full year 2026 financial guidance raised"
- When does Supernus Pharmaceuticals, Inc. report earnings?
- Supernus Pharmaceuticals, Inc.'s next earnings report is expected on 2026-10-29.
Every figure on this page comes from Supernus Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.